|Targets||mTOR | PI3K|
|Description||GDC-0084, a PI3K inhibitor, has been found to have probable antineoplastic effect and could pass blood-brain barrier with favourable penetration. It was just licensed to Novogen and start a Phase II trial for Glioma.|
|B0084-474534||300 mg||$599||In stock|
|Solubility||DMSO: ≥ 6 mg/mL|
|Application||GDC-0084 is a PI3K inhibitor that has been found to have probable antineoplastic effect and could pass blood-brain barrier with favourable penetration.|
|Shelf Life||As supplied, 2 years from the QC date provided on the Certificate of Analysis, when stored properly|
ZSTK474 is a novel phosphatidylinositol 3-kinase (PI3K) inhibitor, which strongly inhibits cancer cell proliferation. Phosphoinositide 3-kinase (PI3K) is a pote...
GDC-0084, a PI3K inhibitor, has been found to have probable antineoplastic effect and could pass blood-brain barrier with favourable penetration. It was just li...
Temsirolimus potently inhibits mTOR kinase activity with IC50 of 1.76 μM, similar to that of rapamycin with IC50 of 1.74 μM.
Leniolisib is a PI3K (phosphatidylinositol 3-kinase) inhibitor. No detailed information has been published yet.
NSC781406 demonstrates potent PI3K inhibition (PI3Kα IC50=2.0 nM) and is a highly potent mTOR inhibitor, with reasonable liver microsome stability.
Copanlisib is a phosphoinositide 3-kinase (PI3K) inhibitor with potential antineoplastic activity. BAY 80-6946 inhibits the activation of the PI3K signaling pat...
CC-115, a DNA-PK and mTOR inhibitor, has been found to have probable anticarcinoma effect. IC50:13 nM and 21 nM for DNA-PK and mTOR respectively.
GSK1059615 is a dual inhibitor of PI3Kα/β/δ/γ (reversible) and mTOR with IC50 of 0.4 nM/0.6 nM/2 nM/5 nM and 12 nM, respectively.
XL PI3K/mTOR inhibitor
An orally bioactive PI3K/mTOR tyrosine kinase inhibitor.
Torin 2 inhibits ATM/ATR/DNA-PK with EC50 of 28 nM/35 nM/118 nM, in PC3 cell lines respectively. It is potentially used as an antineoplastic agent.
PF-04691502 is an agent targeting the phosphatidylinositol 3 kinase (PI3K) and mammalian target of rapamycin (mTOR) in the PI3K/mTOR signaling pathway, with pot...
PI3Kα inhibitor 1
PI3Kα inhibitor 1 is an inhibitor of PI3Kα as well as HDAC and probably have antineoplastic activity. IC50: ＜0.1 μM.
SC-III3 is a scopoletin derivative and has been found to induce the autophagy of hepatoma HepG2 cells so that could be significant in anticancer studies.
PIK-90 is a potent PI3K inhibitor.
IC-87114 is a potent and selective PI3Kδ inhibitor with IC50 of 0.5 μM.
Acalisib, also known as GS-9820, is an inhibitor of the beta and delta isoforms of the 110 kDa catalytic subunit of class IA phosphoinositide-3 kinases (PI3K) ...
SF2523 is a dual inhibitor of phosphatidylinositol 3-kinase and bromodomain-containing protein 4 with IC50 values of 34 nM, 158 nM, 9 nM, 241 nM and 280 nM for ...
BKM120, also called as buparlisib or NVP-BKM120, activity in a range of preclinical cancermodels, specifically inhbits class I PI3K isoforms, which blocks p110α...
AZD2014 is an orally bioavailable inhibitor of the mammalian target of rapamycin (mTOR) with potential antineoplastic activity. AZD2014 inhibits the activity o...
AZD 8186 is a selective PI3Kβ/δ inhibitor (IC50= 0.003 μM for PI3Kβ, and 0.017 μM for PI3Kδ) with potential antineoplastic activity. It shows no significant bin...